Atlanta Capital Partners

Atalanta Therapeutics is a biotechnology company pioneering a new class of RNA interference (RNAi) therapeutics to treat neurodegenerative diseases. The company's proprietary branched siRNA (bsiRNA) platform is designed to achieve broad and deep distribution throughout the central nervous system, overcoming the limitations of traditional siRNA delivery. Atalanta is advancing a pipeline of programs targeting high-value CNS indications, including Huntington's disease, Alzheimer's disease, and Parkinson's disease. The company was founded by leading experts in RNAi and neurodegeneration and is backed by top-tier investors and strategic partnerships with major pharmaceutical companies like Biogen.